Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed LN with ISN/RPS histopathology classes III to V~Exclusion Criteria:~* Patients with biopsy had proven ISN / RPS classes I, II and VI LN~* Patients with previous history of treatment and relapse of lupus nephritis~* Patients who were receiving continuous dialysis for more than two weeks prior to randomization.~* Patients of less than 12 years of age~* Patients who had concurrent infection or illness at the time of enrollment~* Patients who were taking concurrent medications which are supposed to have interactions with MMF or CYC~* Female patients who were pregnant and breastfeeding.~* Patients who did not give consent for participation

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide (Type: EXPERIMENTAL): Participants in this arm received intravenous cyclophosphamide (CYC) in the dose of 0.5 to 1 gram per m2 of body surface area.
- mycophenolate mofetil (Type: EXPERIMENTAL): Patients in this arm received mycophenolate mofetil in the tablet form.

Based on this trial design, predict the completion outcome and termination type (if applicable).